Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 2 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Recs

0
Player Avatar stratton6 (98.84) Submitted: 6/24/2006 6:47:16 PM : Outperform Start Price: $9.74 NBIX Score: -46.35

Looks like it might be a correction. The FDAs letter, albeit strangely worded, was not a rejection.

Featured Broker Partners


Advertisement